ReviewPlant biotechnology journal2026
Protein engineering strategies to optimise recombinant product synthesis and accumulation in Nicotiana benthamiana.
Review in Plant biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rickettsial Diseases and Vaccines: Is There an Opportunity for Plant-Made Vaccine Technology?Biotechnology and bioengineering · 2026Review
- Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Bacteriophage P22 Virus-Like Particles as Nanoscale Protein Scaffolds for Plant Synthetic Biology.Plant biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In plant molecular farming, recombinant products include traditional protein targets, such as antibodies, antigens, and enzymes, but also increasingly refers to high-value peptides, and small molecules produced by heterologous enzymatic pathways. The efficient accumulation and purification of recombinant products requires stable expression and localisation to permissive subcellular environments. Here we discuss innovation in protein engineering and complementary subcellular engineering strategies to tailor Nicotiana benthamiana for recombinant production of proteins, peptides, and small molecules. Three broad themes emerge: (i) targeting proteins via translational fusion of signal sequences can be effectively paired with engineered subcellular environments or synthetic organelles to improve protein folding and stability; (ii) fusion partners can be used to increase accumulation, facilitate purification, or sometimes both, in the case of identified multifunctional protein domains; (iii) co-expression with heterologous enzymes to perform orthogonal post-translational modification can enable the synthesis of unique peptide products. Together, these are some of the strategies that can increase recombinant expression, facilitate complex maturation requirements, shield the product from host cell metabolic processes, or protect the host from toxic product accumulation. The future of protein engineering strategies in N. benthamiana will benefit from advances in other recombinant production systems, genome-wide synthetic biology approaches, and developments in computational protein design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.